Nasonex, Rozerem ads most recalled of 2007

Share this article:
Nasonex ad tops in consumer recall
Nasonex ad tops in consumer recall

DTC TV prescription drug ads featuring an animated bee and a talking beaver were most recalled by consumers during 2007, according to ad performance tracking firm IAG Research.

A 30-second spot featuring Schering-Plough's Nasonex bee was the most recalled broadcast and cable TV ad, followed by a 60-second spot for Takeda's Rozerem featuring the tagline “Your Dreams Miss You.”

Ads for Merck/Schering/Plough's Vytorin and Pfizer's Lipitor featuring Dr. Robert Jarvik followed close behind in terms of consumer ad recall. (See data below).

Most recalled new prescription drug/vaccine ads -- (based on new ads launched in calendar 2007 - 1.1.07 through 12.31.07)

1. Nasonex,Schering-Plough- Animated bee talks about prevention of allergy symptoms, 30- second spot

2. Rozerem, Takeda- Abe Lincoln, talking beaver, man in diving suit at bus stop; "Your Dreams Miss You", 60-second spot

3.Vytorin, Merck/Schering-Plough- Plates of food next to shots of relatives; tuna and peas, Grandma Louise, 60-second spot

4.Lipitor, Pfizer- Dr. Robert Jarvik in white lab coat discusses heart disease, 60-second spot

5.(Tie) Chantix Pfizer- Tortoise and hare, 60-second spot
Vytorin, Merck/Schering-Plough- Plates of food next to shots of realtives; Grandpa Bo, bowtie pasta, 60-second spot

6.(Tie) Lunesta, Sepracor- Luna moth flies into bedrooms, 60-second spot
Cialis Eli Lilly- Couples in various romantic places, 60-second spot

7.(Tie)Gardasil, Merck- Various young women (cowgirl, colorguard, gymnast) Tagline: "One Less," 60-second spot
Rozerem, Takeda- Abe Lincoln, talking beaver, man in diving suit at office; "Your Dreams Miss You," 60-second spot

-courtesy IAG Research

Share this article:

Email Newsletters

More in News

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.